Citadel Advisors
HOWL icon

Citadel Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Citadel Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,600
Closed -$13.2K – 13595
2025
Q1 		$13.2K Sell
13,600
-400
-3% -$524 ﹤0.01% 13409
2024
Q4 		$20.7K Buy
14,000
+13,500
+2,700% +$27.5K ﹤0.01% 13164
2024
Q3 		$1.06K Sell
500
-800
-62% -$1.82K ﹤0.01% 13910
2024
Q2 		$3.17K Sell
1,300
-6,000
-82% -$28.8K ﹤0.01% 13618
2024
Q1 		$47.3K Buy
7,300
+7,200
+7,200% +$42K ﹤0.01% 12222
2023
Q4 		$386 Buy
+100
New +$255 ﹤0.01% 14047

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's HOWL Position: Q1 2026 in Review

Citadel Advisors opened a new position in Werewolf Therapeutics (HOWL) in Q1 2026: 10,382 shares worth $8.64K. The stake represents ﹤0.01% of the portfolio and ranks #12776 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HOWL as recently as Q3 2025.

Citadel Advisors first reported a position in HOWL in Q1 2022 and has held it in 8 quarters since. The position peaked at $304K in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Citadel Advisors held 10,382 shares of Werewolf Therapeutics worth $8.64K as of Q1 2026.
  • Werewolf Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12776 holding.
  • Citadel Advisors first reported a position in Werewolf Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Citadel Advisors's Werewolf Therapeutics position peaked at $304K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.